Covestor’s enGene Therapeutics ENGN Stock Holding History

Covestor’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43K	Buy	+21,451	New	+$39.7K	0.03%	812

Other funds holding ENGN

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return

Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Covestor's ENGN Position: Q3 2026 in Review

Covestor opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 21,451 shares worth $43K. The stake represents 0.03% of the portfolio and ranks #812 among its holdings.

6 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

Covestor held 21,451 shares of enGene Therapeutics worth $43K as of Q3 2026.
enGene Therapeutics was a new Covestor position in Q3 2026.
enGene Therapeutics made up 0.03% of Covestor's portfolio in Q3 2026, its #812 holding.
6 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.